140,570 Shares in Harrow, Inc. $HROW Purchased by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP acquired a new position in Harrow, Inc. (NASDAQ:HROW) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 140,570 shares of the company’s stock, valued at approximately $4,293,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Teacher Retirement System of Texas raised its position in shares of Harrow by 4.1% in the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock worth $259,000 after acquiring an additional 332 shares in the last quarter. Pale Fire Capital SE boosted its position in shares of Harrow by 6.8% during the second quarter. Pale Fire Capital SE now owns 8,683 shares of the company’s stock valued at $265,000 after purchasing an additional 550 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Harrow by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock worth $483,000 after purchasing an additional 790 shares during the period. Police & Firemen s Retirement System of New Jersey grew its stake in Harrow by 16.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 7,273 shares of the company’s stock worth $222,000 after purchasing an additional 1,041 shares during the period. Finally, Quarry LP bought a new position in Harrow in the first quarter worth $32,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

HROW has been the topic of a number of research reports. Lake Street Capital boosted their target price on shares of Harrow from $42.00 to $70.00 and gave the company a “buy” rating in a report on Monday, September 29th. Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Wednesday, October 8th. Craig Hallum upped their price objective on shares of Harrow from $54.00 to $64.00 and gave the stock a “buy” rating in a report on Tuesday, September 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $94.00 target price on shares of Harrow in a report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $71.43.

Harrow Stock Performance

Shares of Harrow stock opened at $45.75 on Monday. Harrow, Inc. has a 1 year low of $20.85 and a 1 year high of $50.72. The firm’s 50-day moving average is $40.12 and its 200 day moving average is $36.77. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -457.45 and a beta of 0.07. The company has a debt-to-equity ratio of 5.21, a current ratio of 2.72 and a quick ratio of 2.52.

Harrow (NASDAQ:HROW) last issued its earnings results on Monday, November 10th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.11. The business had revenue of $71.64 million during the quarter, compared to analysts’ expectations of $73.70 million. Harrow had a negative net margin of 1.99% and a positive return on equity of 28.71%. Sell-side analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current fiscal year.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.